Strategies and advances in targeting adaptive immunity to cure chronic hepatitis B
DOI:10.3969/j.issn.1001-5256.2021.05.005
- VernacularTitle:靶向适应性免疫治愈慢性乙型肝炎策略及进展
- Author:
Wei ZHU
1
;
Xiaoyong ZHANG
;
Daqian ZHANG
;
Jinlin HOU
Author Information
1. Center of Hepatology, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
- Publication Type:Research Article
- Keywords:
Hepatitis B Virus;
Hepatitis B, Chronic;
Adaptive Immunity;
Therapeutics
- From:
Journal of Clinical Hepatology
2021;37(5):1016-1021.
- CountryChina
- Language:Chinese
-
Abstract:
Chronic hepatitis B (CHB) is a major global public health issue, and although direct-acting antiviral agents can control hepatitis B virus (HBV) replication, it is difficult to achieve the cure of CHB. Host adaptive immune response plays a key role in eliminating HBV, and it is expected to achieve the functional cure of CHB by rebuilding the patient’s adaptive immunity. Great progress has been made in therapeutic vaccines, cellular immunotherapy, immune checkpoint blockade, T cell metabolic reprogramming, and strategies of neutralizing antibody targeting adaptive immunity for the treatment of hepatitis B. This article summarizes the above-mentioned therapies for hepatitis B in recent years.
